Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 6, 2011, Pages 710-715

  Passerotti, Carlo C ^a,b   Srougi, Miguel ^a   Bomfim, Alexandre C ^b   Martins, Joao Roberto M ^b   Leite, Katia R M ^a   dos Reis, Sabrina T ^a   Sampaio, Lucia O ^b   Ortiz, Valdemar ^b   Dietrich, Carl P ^b   Nader, Helena B ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Human bladder neoplasms; Transitional cell carcinoma; Tumor marker; Urinary hyaluronan

Indexed keywords

HYALURONIC ACID;

ARTICLE; BLADDER TUMOR; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER RISK; CONTROLLED STUDY; CYSTECTOMY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; HUMAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; PATHOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; RANK SUM TEST; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STUDENT T TEST; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINALYSIS; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CARCINOMA, TRANSITIONAL CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 81055125114     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.10.006     Document Type: Article

References (28)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:1-25.
2. Ro J.Y., Staerkel G.A., Ayala A.G. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 1992, 19:435-453.
3. Althausen A.F., Prout G.R., Daly J.J. Noninvasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976, 116:575-580.
4. Heney N.M., Proppe K., Prout G.R., et al. Invasive bladder cancer: Tumor configuration, lymphatic invasion, and survival. J Urol 1983, 130:895-897.
5. Heney N.M., Ahmed S., Flanagan M.J., et al. Superficial bladder cancer: Progression and recurrence. J Urol 1983, 130:1083-1086.
6. Lutzeyer W., Rubben H., Dahm H. Prognostic parameters in superficial bladder cancer: An analysis of 315 cases. J Urol 1982, 127:250-252.
7. Laurent T.C., Fraser J.R. Hyaluronan. FASEB J 1992, 6:2397-2404.
8. Martins J.R., Passerotti C.C., Maciel R.M., et al. Practical determination of hyaluronan by a new noncompetitive fluorescence-based assay on serum of normal and cirrhotic patients. Anal Biochem 2003, 319:65-72.
9. Martins J.R., Furlanetto R.P., Oliveira L.M., et al. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2004, 60:726-733.
10. Lotan Y., Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology 2003, 61:109-118. Discussion 118.
11. Song J.W., DU L.L., Zhao X.W., et al. Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder. Zhonghua Zhong Liu Za Zhi 2009, 31:274-277.
12. Hanke M., Hoefig K., Merz H., et al. A robust methodology to study urine microRNA as tumor marker: MicroRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010, 28:655-661.
13. Sozen S., Eskicorabci S., Ozen H. Urinary markers for urothelial cancer. BJU Int 2003, 92:531-533.
14. Passerotti C.C., Bonfim A., Martins J.R., et al. Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder. Eur Urol 2006, 49:71-75.
15. Hallen A. Chromatography of acidic glycosaminoglycans on DEAE-cellulose. J Chromatogr 1972, 71:83-91.
16. Bitter T., Muir H.M. A modified uronic acid carbazole reaction. Anal Biochem 1962, 4:330-334.
17. Linker A., Meyer K., Hoffman P. The production of hyaluronate oligosaccharides by leech hyaluronidase and alkali. J Biol Chem 1960, 235:924-927.
18. Hardingham T.E., Muir H. The specific interaction of hyaluronic acid with cartilage proteoglycans. Biochim Biophys Acta 1972, 279:401-405.
19. Hascall V.C., Heinegard D. Aggregation of cartilage proteoglycans. I. The role of hyaluronic acid. J Biol Chem 1974, 249:4232-4241.
20. Delpech B., Bertrand P., Maingonnat C. Immunoenzymoassay of the hyaluronic acid-hyaluronectin interaction: Application to the detection of hyaluronic acid in serum of normal subjects and cancer patients. Anal Biochem 1985, 149:555-565.
21. Laurent U.B., Tengblad A. Determination of hyaluronate in biological samples by a specific radioassay technique. Anal Biochem 1980, 109:386-394.
22. Kongtawelert P., Ghosh P. A method for the quantitation of hyaluronan (hyaluronic acid) in biological fluids using a labeled avidin-biotin technique. Anal Biochem 1990, 185:313-318.
23. Kongtawelert P., Ghosh P. An enzyme-linked immunosorbent-inhibition assay for quantitation of hyaluronan (hyaluronic acid) in biological fluids. Anal Biochem 1989, 178:367-372.
24. Rossler A. An ultrasensitive, nonisotopic immunoassay for hyaluronan using the streptavidin-biotin system. Clin Chim Acta 1998, 270:101-114.
25. Lokeshwar V.B., Obek C., Soloway M.S., et al. Tumor-associated hyaluronic acid: A new sensitive and specific urine marker for bladder cancer. Cancer Res 1997, 57:773-777.
26. Lokeshwar V.B., Block N.L. HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol Clin North Am 2000, 27:53-61.
27. Lokeshwar V.B., Obek C., Pham H.T., et al. Urinary hyaluronic acid and hyaluronidase: Markers for bladder cancer detection and evaluation of grade. J Urol 2000, 163:348-356.
28. Simon M.A., Lokeshwar V.B., Soloway M.S. Current bladder cancer tests: Unnecessary or beneficial?. Crit Rev Oncol Hematol 2003, 47:91-107.